Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

6. november 2026 oppdatert av: Novartis Pharmaceuticals

A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).

Studieoversikt

Detaljert beskrivelse

This is a global, phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of remibrutinib in adult participants with severe CPUO.

The design includes 4 periods, for a total duration of up to 60 weeks:

  • Screening period: up to 4 weeks.
  • Double-blind treatment period (treatment period 1, TP1): 24 weeks of double-blind treatment with remibrutinib or matching placebo
  • Open-label treatment period (treatment period 2, TP2): 28 weeks of open-label treatment with remibrutinib. The participants randomized to the placebo arm will be switched to remibrutinib at Week 24.
  • Safety follow-up period: 4 weeks of treatment-free safety follow-up.

Studietype

Intervensjonell

Registrering (Antatt)

180

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Novartis Pharmaceuticals
  • Telefonnummer: +41613241111

Studiesteder

      • CABA, Argentina, C1181ACH
        • Rekruttering
        • Novartis Investigative Site
    • Buenos Aires
      • Caba, Buenos Aires, Argentina, C1119ACN
        • Rekruttering
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DBS
        • Rekruttering
        • Novartis Investigative Site
    • Ontario
      • Hamilton, Ontario, Canada, L8L 3C3
        • Rekruttering
        • Novartis Investigative Site
    • Quebec
      • Québec, Quebec, Canada, G1W 4R4
        • Rekruttering
        • Novartis Investigative Site
    • Alabama
      • Cullman, Alabama, Forente stater, 35058
        • Rekruttering
        • Aller Vie Health-Cullman
        • Hovedetterforsker:
          • John Anderson
        • Ta kontakt med:
    • Florida
      • Miami, Florida, Forente stater, 33126
    • Georgia
      • Savannah, Georgia, Forente stater, 31406
        • Rekruttering
        • Aeroallergy Research Laboratories
        • Hovedetterforsker:
          • Brad Goodman
        • Ta kontakt med:
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46256
        • Rekruttering
        • Dawes Fretzin Clinical Rea Group
        • Hovedetterforsker:
          • Kenneth Dawes
        • Ta kontakt med:
      • New Albany, Indiana, Forente stater, 47150
        • Rekruttering
        • Southern IN Clinical Trials
        • Ta kontakt med:
        • Hovedetterforsker:
          • Megan Landis
    • New York
      • The Bronx, New York, Forente stater, 10455
        • Rekruttering
        • Equity Medical
        • Hovedetterforsker:
          • Michael Cameron
        • Ta kontakt med:
    • Ohio
      • Boardman, Ohio, Forente stater, 44512
        • Rekruttering
        • Optima Research-Boardman
        • Hovedetterforsker:
          • Patrick Shannon
        • Ta kontakt med:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15241
        • Rekruttering
        • Allergy and Clinical Immunology Associates
        • Hovedetterforsker:
          • Michael Palumbo
        • Ta kontakt med:
    • South Carolina
      • North Charleston, South Carolina, Forente stater, 29420
        • Rekruttering
        • National Allergy and Asthma Research LLS
        • Hovedetterforsker:
          • John T Ramey
        • Ta kontakt med:
    • Texas
      • Pflugerville, Texas, Forente stater, 78660
        • Rekruttering
        • Austin Inst for Clinical Research
        • Hovedetterforsker:
          • Edward Lain
        • Ta kontakt med:
    • Fukuoka
      • Kitakyushu, Fukuoka, Japan, 8078556
        • Rekruttering
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 2400013
        • Rekruttering
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto, Kumamoto, Japan, 8620950
        • Rekruttering
        • Novartis Investigative Site
    • Osaka
      • Habikino, Osaka, Japan, 5838588
        • Rekruttering
        • Novartis Investigative Site
      • Sakai, Osaka, Japan, 5938324
        • Rekruttering
        • Novartis Investigative Site
    • Tokyo
      • Tachikawa, Tokyo, Japan, 1900023
        • Rekruttering
        • Novartis Investigative Site
      • Seoul, Sør -Korea, 03722
        • Rekruttering
        • Novartis Investigative Site
      • Seoul, Sør -Korea, 07804
        • Rekruttering
        • Novartis Investigative Site
    • Gyeonggi-do
      • Ansan, Gyeonggi-do, Sør -Korea, 15355
        • Rekruttering
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  • Participant must be ≥ 18 years of age, at the time of signing the informed consent.
  • Participants with chronic pruritus for at least 4 months prior to screening.
  • Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (e.g., excluding chronic pruritus related to primary dermatological or systemic conditions, neuropathic or psychogenic origin or secondary to drugs or other allergen exposures).
  • Chronic pruritus must affect at least 2 of the following body areas: trunk, arms, or legs (cannot be unilateral and/or dermatomal in distribution).
  • Participants with ongoing, severe chronic pruritus despite the use of emollients and who are candidates for systemic therapy.
  • Participants must have severe itch defined by a WI-NRS ≥7 at screening; score scale ranges from 0 to 10; higher score indicates worse itch.
  • Participants must have an average WI-NRS ≥7 over the 7 days prior to randomization/baseline visit.
  • The average WI-NRS score over the preceding 7 days prior to the randomization/baseline visit will be calculated based on the daily WI-NRS scores (0-10).
  • Participants must have PGIS of pruritus scored as 3 "severe" at screening and baseline visits.

Key Exclusion Criteria:

  • Any active skin conditions (e.g., atopic dermatitis, psoriasis, etc.) that may interfere with the assessment of CPUO.
  • Known systemic condition(s) or medication(s) that are considered by the investigator to be the primary cause of current pruritus.
  • Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include but are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected HIV infection.
  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • Significant bleeding risk or coagulation disorders. History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAIDs), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion). Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
  • History or current hepatic disease, including but not limited to, acute or chronic hepatitis, cirrhosis or hepatic failure or aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Remibrutinib

Remibrutinib film coated tablets

Oral administration of remibrutinib

Andre navn:
  • LOU064
Eksperimentell: Placebo followed by remibrutinib

Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib).

Oral administration of remibrutinib

Andre navn:
  • LOU064

Oral administration of matching placebo.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS)
Tidsramme: Baseline, Week 12

The WI-NRS is a patient-reported outcome (PRO) instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity.

Baseline, Week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of participants achieving ≥4 point reduction from baseline in WI NRS
Tidsramme: Baseline, Week 4

The WI-NRS is a PRO instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity.

Baseline, Week 4
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)
Tidsramme: Week 12

The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome.

Week 12
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)
Tidsramme: Week 24

The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome.

Week 24
Change from baseline in Pruritus-related Sleep Disturbance Numerical Rating Scale (SD-NRS)
Tidsramme: Week 12

The SD-NRS is a PRO instrument used to assess the degree of sleep disturbance caused by pruritus (itch). The score range is from 0 (No sleep disturbance) to 10 (Worst possible sleep disturbance). Higher scores indicate greater sleep disturbance due to pruritus.

Week 12
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to Week 52

Number of participants with AEs and SAEs.

Up to Week 52

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. august 2026

Primær fullføring (Antatt)

19. desember 2029

Studiet fullført (Antatt)

15. april 2030

Datoer for studieregistrering

Først innsendt

7. juli 2026

Først innsendt som oppfylte QC-kriteriene

7. juli 2026

Først lagt ut (Faktiske)

13. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • CLOU064R12301
  • 2025-524497-41 (Annen identifikator: EU CTIS number)
  • 2025 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere